Navigation Links
angelMD Completes Investment in Bleeding Detection Medical Device Company

angelMD announced the closure of a new syndicate investment in Saranas, a promising new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this first investment in Saranas by angelMD members, and this angelMD syndicate is part of Saranas’ recently announced $4 million Series B financing round.

Saranas is working to create a way to quickly and accurately diagnose complications in vascular access procedures, while lowering patient and provider costs. Every year, twenty million American patients undergo these procedures to provide longer term access for intravenous (IV) medical treatments, and as many as a million of these patients experience life-threatening complications as a result of an inability to quickly account for problems like internal bleeding. These issues cost patients and providers a collective $8.4B dollars each year.

“With the growth of value-based insurance reimbursements combined with the increasing popularity of intravenous heart procedures, patients and doctors are demanding better procedural outcomes,” said Parsley. “This innovative real-time bleeding detection device by Dr. Razavi is designed to be integrated directly into common catheter sheaths, and I’m confident many existing cardiac medical device companies will see the immediate value of this technology.”

Saranas is angelMD’s first investment of technology originating from the prestigious Texas Heart Institute at the Texas Medical Center.

Saranas CEO Zaffer Syed said, “We are thrilled to be adding angelMD to our investor base. With access to physician investors, angelMD brings a strong track record of adding real value to its portfolio companies. This Series B financing reflects a deep commitment to Saranas’ innovative approach for enhancing patient outcomes during vascular access procedures.”

“Saranas has the management team and an experienced board that will be able to see this innovative technology through FDA clearance, and we are excited to help this company grow and become an industry leader,” concluded Parsley.

About angelMD
angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit

About Saranas
Saranas is a privately held Houston, Texas-based medical device company focused on improving patient outcomes through early detection of internal bleeding complications. The company’s patented introducer sheath technology for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more on their pioneering technology, visit

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. 3 angelMD Startups Make Livestrong Big C Semi-finals
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Novira Therapeutics Completes $25 Million Series A Financing
4. bioRASI Completes Acquisition of Ukrainian CRO
5. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
6. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
7. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
8. Oligomerix, Inc. Completes Series B Financing
9. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
10. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
11. Boston Scientific Completes $1.05 Billion Senior Notes Offering
Post Your Comments:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):